摘要

【摘要】
目的 探讨文拉法辛治疗突发性耳聋合并焦虑抑郁疗效。

方法 选取我院2022年8月-2024年8月收治的104例突发性耳聋合并焦虑抑郁患者，两组患者均给予基础治疗，对照组增加放松训练，观察组在对照组基础上增加文拉法辛口服，对比两组患者焦虑抑郁情绪、临床疗效、血清5-羟色胺（5-hydroxytryptamine，5-HT），神经肽Y（neuropeptide，YNPY）水平、心理弹性评分、应对方式评分、睡眠质量评分、生活质量评分及不良反应。

结果 治疗后，两组焦虑评分、抑郁评分均降低，且观察组更低（P<0.05）。治疗后，观察组总有效率高于对照组（P<0.05）。两组血清5-HT、NPY水平均升高，且观察组更高（P<0.05）。两组心理弹性量表评分、简易应对方式问卷积极应对评分均升高，且观察组更高（P<0.05）。两组匹兹堡睡眠质量指数评分均降低，且观察组更低，两组世界卫生组织生存质量测定量表简表评分均升高，且观察组更高（P<0.05）。两组不良反应发生率无统计学差异（P>0.05）。

结论 文拉法辛治疗突发性耳聋合并焦虑抑郁患者可以改善焦虑抑郁情绪，减轻临床症状，改善心理状况，调节神经递质水平，提高睡眠和生活质量。

关键词：【关键词】突发性耳聋；文拉法辛；焦虑；抑郁；5-羟色胺；神经肽Y

ABSTRACT

[Abstract]
Objective To explore the effect of venlafaxine on sudden deafness complicated with anxiety and depression.

Methods 104 patients with sudden deafness combined with anxiety and depression admitted to our hospital from August 2022 to August 2024 were selected. All patients were given conventional symptomatic treatment, the control group were given relaxation training, and the observation group was given venlafaxine orally on the basis of the control group. The anxiety and depression mood, clinical efficacy, serum 5-hydroxytryptamine (5-HT) and neuropeptide Y (NPY) levels, psychological resilience score, coping style score, sleep quality score, quality of life score and adverse reactions were compared in both groups.

Results After treatment, anxiety score (SAS), depression score (SDS) of both groups were decreased, and the observation group was lower (P<0.05). After treatment, the total effective rate of observation group was higher than that of control group (P<0.05). Serum 5-HT and NPY levels were increased in both groups, and observation group was higher (P<0.05). Connor davidson resilience scale (CD-RISC) score and simple coping style questionnaire (SCSQ) positive coping score were increased in both groups, and higher in observation group (P<0.05). Pittsburgh sleep quality index (PSQI) score decreased in both groups, and the observation group was lower, and WHO quality of life measurement scale brief version (WHOQOL-BREF) score increased in both groups, and the observation group was higher (P<0.05). There was no difference in the incidence of adverse reactions in both groups (P>0.05).

Conclusion   Venlafaxine can improve anxiety and depression, reduce clinical symptoms, improve psychological status, regulate neurotransmitter levels, and improve sleep and quality of life in sudden deafness patients with anxiety and depression.

Key words: [Key words] Sudden deafness; Venlafaxine; Anxiety; depressed; 5-hydroxytryptamine; Neuropeptide Y